Design of a phase II dose range finding, efficacy and safety study of the Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in relapsing multiple sclerosis patients

被引：0
|
作者：
Montalban, X. [1 ]
Bojanowski, J. [2 ]
Martin, E. [2 ]
Willmer, J. [2 ]
机构：
[1] Vall dHebron Univ Hosp & Res Inst, Barcelona, Spain
[2] EMD Serono Res & Dev Inst Inc, Billerica, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P675
引用
收藏
页码：324 / 324
页数：1
相关论文
共 50 条
  • [1] Primary Analysis of a Randomized, Placebo-Controlled, Phase II Study of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib (M2951) in Patients with Relapsing Multiple Sclerosis
    Montalban, Xavier
    Arnold, Douglas L.
    Weber, Martin
    Staikov, Ivan
    Piasecka-Strycznska, Karolina
    Willmer, Jonathan
    Martin, Emily
    Dangond, Fernando
    Wolinsky, Jerry S.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 10 - 11
  • [2] Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing Multiple sclerosis: a randomised, placebo-controlled, phase 2 study
    Montalban, X.
    Arnold, D.
    Weber, M.
    Staikov, I.
    Piasecka-Stryczynska, K.
    Martin, E.
    Syed, S.
    Dangond, F.
    Wolinsky, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 32 - 32
  • [3] EFFICACY AND SAFETY OF THE BRUTON'S TYROSINE KINASE INHIBITOR EVOBRUTINIB (M2951) IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS OVER 48 WEEKS: A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 STUDY
    Montalban, Xavier
    Arnold, Douglas L.
    Weber, Martin S.
    Staikov, Ivan
    Piasecka-Stryczynska, Karolina
    Gillett, Alan
    Martin, Emily C.
    Syed, Sana
    Dangond, Fernando
    Wolinsky, Jerry S.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2019, 90 (E7):
  • [4] Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib (M2951) in Patients with Relapsing Multiple Sclerosis over 48 Weeks: a Randomized, Placebo-Controlled, Phase 2 Study
    Montalban, Xavier
    Arnold, Douglas L.
    Weber, Martin S.
    Staikov, Ivan
    Piasecka-Stryczynska, Karolina
    Martin, Emily C.
    Dangond, Fernando
    Wolinsky, Jerry S.
    NEUROLOGY, 2019, 92 (15)
  • [5] Primary analysis of a randomised, placebo-controlled, phase 2 study of the Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis
    Montalban, X.
    Arnold, D. L.
    Weber, M. S.
    Staikov, I.
    Piasecka-Stryczynska, K.
    Willmer, J.
    Martin, E.
    Dangond, F.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 984 - 985
  • [6] Safety of the bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis during an open-label extension to a phase ii study
    Montalban, X.
    Arnold, D. L.
    Weber, M.
    Staikov, I.
    Piasecka-Stryczynska, K.
    Martin, E.
    Mandel, M.
    Ona, V.
    Zima, Y.
    Tomic, D.
    Wolinsky, J.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 233 - 233
  • [7] Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis over 48 Weeks: a Randomised, Placebo-controlled, Phase 2 Study
    Bojanowski, J.
    Montalban, X.
    Arnold, D. L.
    Weber, M. S.
    Staikov, I.
    Piasecka-Stryczynska, K.
    Martin, E. C.
    Syed, S.
    Dangond, F.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP69 - NP70
  • [8] Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib for Relapsing Multiple Sclerosis Over 3.5 Years of Treatment: An Ongoing Phase II Open-Label Extension
    Montalban, X.
    Wolinsky, J. S.
    Arnold, D. L.
    Weber, M. S.
    Piasecka-Stryczynska, K.
    Tomic, D.
    Seitzinger, A.
    Guehring, H.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 53 - 53
  • [9] Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib for Relapsing Multiple Sclerosis Over 3.5 Years of Treatment: An Ongoing Phase II Open-Label Extension
    Montalban, Xavier
    Wolinsky, Jerry S.
    Arnold, Douglas L.
    Weber, Martin S.
    Piasecka-Stryczynska, Karolina
    Tomic, Davorka
    Seitzinger, Andrea
    Guehring, Hans
    NEUROLOGY, 2023, 100 (17)
  • [10] T cell mediated experimental CNS autoimmunity induced by PLP in SJL mice is modulated by Evobrutinib (M2951) a novel Bruton's tyrosine kinase inhibitor
    Boschert, U.
    Crandall, T.
    Pereira, A.
    Higginbotham, G.
    Wu, Y.
    Grenningloh, R.
    Savinainen, A.
    Bender, A.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 327 - 327
12345